Foundation News

Stay up-to-date with the most current news and information about the Crohn's & Colitis Foundation, as well as Crohn's disease and ulcerative colitis.

Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Disease (IBD) Receives Funding

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel disease (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.

May 17, 2018

Leading Patient & Professional Organizations Announce Funding to Improve Communications & Address Shared Decision-making in Inflammatory Bowel Diseases

The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.

April 17, 2018

The Crohn's & Colitis Foundation Selects Diversigen, Inc. as a Preferred Provider for Metagenomics and Microbiome Analysis Services

Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform.

April 17, 2018

Crohn’s & Colitis Foundation Receives $5 Million to Fund Innovative Translational and Clinical IBD Research

The Crohn’s & Colitis Foundation announced that it received a $5 million pledge from the Litwin family to fund novel, high-risk/high-reward research ideas in the early stage of exploration that could advance the field of inflammatory bowel diseases (IBD) research.

October 30, 2017

Partnering to Accelerate Science

The Crohn’s & Colitis Foundation (the Foundation) celebrates the visionary academic and industry scientists, The Leona M. and Harry B. Helmsley Charitable Trust, IBD patients, and Foundation staff who are partnering to create and sustain IBD Plexus®, a first-of-its-kind research information exchange platform designed to centralize data and biosamples from diverse research studies. The powerful new initiative is designed to advance our understanding of Crohn’s disease and ulcerative colitis, or inflammatory bowel diseases (IBD), and significantly accelerate research driving toward precision medicine and cures for IBD.

October 23, 2017

Crohn's & Colitis Foundation Applauds Passage of Restroom Access Legislation in New York State

The Crohn’s & Colitis Foundation released the following statement today after the New York State Senate passed the Crohn’s & Colitis Fairness Act (S3295).

June 19, 2017

Crohn’s & Colitis Foundation Welcomes New National Trustees

The Crohn’s & Colitis Foundation (the Foundation) is pleased to announce seven new members of its National Board of Trustees, which oversees the management of the organization’s policies, practices, principles, affairs, funds, and property.

April 20, 2017